Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

AC Immune (ACIU) Research & Development (2016 - 2026)

AC Immune has reported Research & Development over the past 11 years, most recently at -$15.0 million for Q1 2026.

  • Quarterly Research & Development rose 15.28% to -$15.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$65.0 million through Mar 2026, up 9.01% year-over-year, with the annual reading at -$70.6 million for FY2025, 1.14% up from the prior year.
  • Research & Development was -$15.0 million for Q1 2026 at AC Immune, down from -$13.3 million in the prior quarter.
  • Over five years, Research & Development peaked at -$13.3 million in Q4 2025 and troughed at -$20.3 million in Q2 2025.
  • The 5-year median for Research & Development is -$16.3 million (2025), against an average of -$16.3 million.
  • Year-over-year, Research & Development rose 28.01% in 2022 and then decreased 24.54% in 2024.
  • A 5-year view of Research & Development shows it stood at -$15.7 million in 2022, then fell by 5.08% to -$16.5 million in 2023, then decreased by 9.15% to -$18.0 million in 2024, then rose by 26.24% to -$13.3 million in 2025, then dropped by 12.84% to -$15.0 million in 2026.
  • Per Business Quant, the three most recent readings for ACIU's Research & Development are -$15.0 million (Q1 2026), -$13.3 million (Q4 2025), and -$16.3 million (Q3 2025).